Study guide
13.4 Dementia vs. Delirium vs. Depression: Differential Diagnostics & Management
ANCC Adult-Gerontology Primary Care Nurse Practitioner AGPCNP-BC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The AGPCNP-BC Examination: Blueprint, Format & Scoring
1.1 The AGPCNP-BC Blueprint, Exam Format, Scoring, Eligibility & Renewal
2 Chapter 2: Assessment Foundations & Lifespan Considerations
2.1 Comprehensive Health History, Symptom Analysis & Lifespan Variations 2.2 Physical Examination Techniques & Age-Related Physiological Changes 2.3 Functional Assessment (Katz ADL / Lawton IADL) & Frailty Syndromes 2.4 Psychosocial, Nutritional, Cognitive & Mental Health Screening Instruments 2.5 Health Screening Guidelines (USPSTF) & Adult Immunization Schedules (CDC/ACIP)
3 Chapter 3: Diagnostic Reasoning & Clinical Interpretation
3.1 Diagnostic Reasoning, Clinical Decision-Making & Differential Diagnosis Formulation 3.2 Routine & Specialized Laboratory Interpretation 3.3 Diagnostic Imaging, ECG Interpretation & Pulmonary Function Testing 3.4 Evidence-Based Testing, Pre-Test Probability & Choosing Wisely Principles
4 Chapter 4: Cardiovascular Disorders
4.1 Hypertension: 2025 AHA/ACC Guideline, Resistant HTN & Secondary HTN 4.2 Dyslipidemia & ASCVD Risk Calculation, Statin Therapy & Non-Statin Agents 4.3 Coronary Artery Disease, Stable Angina & Post-ACS Outpatient Management 4.4 Heart Failure (HFrEF/HFpEF), Atrial Fibrillation & Peripheral Vascular Disease
5 Chapter 5: Respiratory Disorders
5.1 Asthma: GINA 2026 Guidelines, Phenotypes, Stepwise Pharmacotherapy & Action Plans 5.2 COPD: GOLD 2026 Report, ABE Staging, Triple Inhalers & Exacerbations 5.3 Lower Respiratory Infections (CAP, Bronchitis), Pleural Disease & Solitary Pulmonary Nodules
6 Chapter 6: HEENT & Allergic/Immunologic Disorders
6.1 Eye & Vision Disorders in Adult-Gerontology Primary Care 6.2 Ear, Hearing & Vestibular Disorders 6.3 Nose, Sinus, Oropharyngeal & Oral Cavity Disorders 6.4 Allergic & Immunologic Disorders: Anaphylaxis, Urticaria, Angioedema & Immunodeficiency
7 Chapter 7: Endocrine & Metabolic Disorders
7.1 Type 2 Diabetes Mellitus: ADA Standards of Care, Pharmacotherapy & Microvascular Complications 7.2 Thyroid Disorders: Hypothyroidism, Hyperthyroidism, Thyroiditis & Nodules 7.3 Adrenal & Pituitary Disorders: Adrenal Insufficiency, Cushing's, Hyperaldosteronism & Hypopituitarism 7.4 Metabolic Bone Disease: Osteopenia, Osteoporosis (FRAX, DEXA) & Hyperparathyroidism
8 Chapter 8: Gastrointestinal & Hepatic Disorders
8.1 Upper GI Disorders: GERD, Barrett's Esophagus, PUD, H. pylori & Gastritis 8.2 Lower GI Disorders: Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD) & Diverticular Disease 8.3 Hepatobiliary Disorders: MASLD/MASH, Viral & Alcoholic Hepatitis, Cirrhosis & Cholelithiasis 8.4 Acute & Chronic Abdominal Pain Syndromes, GI Bleeding & Colorectal Cancer Screening
9 Chapter 9: Renal, Urological & Men's Health
9.1 Chronic Kidney Disease: KDIGO Staging, Albuminuria Management & Renoprotective Strategies 9.2 Urinary Tract Infections (Uncomplicated, Complicated, Recurrent), Pyelonephritis & Microscopic Hematuria 9.3 Men's Health: Benign Prostatic Hyperplasia, Prostatitis, Epididymitis & Erectile Dysfunction
10 Chapter 10: Musculoskeletal & Rheumatologic Disorders
10.1 Degenerative & Overuse Musculoskeletal Disorders: Osteoarthritis, Tendinopathies & Spine Disorders 10.2 Autoimmune Rheumatologic Disorders: Rheumatoid Arthritis, SLE, Polymyalgia Rheumatica & Giant Cell Arteritis 10.3 Crystal Arthropathies & Fibromyalgia: Gout, Pseudogout & Centralized Pain Syndromes
11 Chapter 11: Neurological & Psychiatric Disorders
11.1 Headaches (Migraine, Tension, Cluster) & Cranial Neuralgias 11.2 Cerebrovascular Disease, TIA, Peripheral Neuropathies & Movement Disorders (Parkinson's) 11.3 Mood & Anxiety Disorders: Major Depressive Disorder, Generalized Anxiety Disorder & PTSD 11.4 Substance Use Disorders: Alcohol, Tobacco, Opioids & Cannabis in Primary Care
12 Chapter 12: Dermatologic, Hematologic & Infectious Disease
12.1 Primary Dermatologic Lesions, Inflammatory Dermatoses & Cutaneous Malignancies 12.2 Common Infectious Diseases: Skin/Soft Tissue Infections, Tick-Borne Illnesses & Viral Syndromes 12.3 Sexually Transmitted Infections (STIs): CDC Guidelines, Screening & Partner Management 12.4 Hematologic Disorders: Anemias (Microcytic, Normocytic, Macrocytic), Leukopenia & Coagulopathies
13 Chapter 13: Geriatric Syndromes, Pharmacology & Palliative Care
13.1 The Geriatric 5Ms Framework, Multimorbidity & Polypharmacy Deprescribing 13.2 Beers Criteria 2023 Update & STOPP/START Prescribing Rules 13.3 Pharmacokinetics, Pharmacodynamics & Pharmacogenomics Across the Adult Lifespan 13.4 Dementia vs. Delirium vs. Depression: Differential Diagnostics & Management 13.5 Falls, Mobility Impairment, Pressure Injury Prevention & Palliative Care Transitions
14 Chapter 14: Gynecologic & Women's Health
14.1 Contraceptive Management, Emergency Contraception & Preconception Counseling 14.2 Perimenopause, Menopause & Hormone Replacement Therapy (HRT) 14.3 Gynecologic Infections (Vaginitis, PID), Abnormal Uterine Bleeding & Cervical Cancer Screening (USPSTF/ASCCP)
15 Chapter 15: Plan-of-Care Process: Behavior Change, Education & Care Coordination
15.1 Behavioral Change: Motivational Interviewing, Models & Theories 15.2 Patient Education, Shared Decision-Making, Referrals, Care Coordination & Plan Reassessment
16 Chapter 16: APRN Professional Practice, Ethics, Policy & Quality Improvement
16.1 APRN Scope of Practice, Consensus Model, Collaborative Practice & Credentialing 16.2 Bioethics, Informed Consent, Advance Directives & Surrogate Decision-Making 16.3 Environmental & Social Determinants of Health, Health Equity & Culturally Responsive Care 16.4 Evidence-Based Practice (EBP), Quality Improvement (QI) Methodologies & Healthcare Economics
13.4 Dementia vs. Delirium vs. Depression: Differential Diagnostics & Management
Key Takeaways Explain This Topic AI
The '3 Ds' (Delirium, Dementia, Depression) share overlapping neurobehavioral features but diverge fundamentally in onset, course, alertness, attention, and reversibility.
Delirium is an acute, fluctuating medical emergency of cholinergic deficiency characterized by inattention and altered consciousness; the Confusion Assessment Method (CAM) is the gold-standard diagnostic instrument.
Hypoactive delirium accounts for over 50% of delirium presentations in older adults, presenting with somnolence, apathy, and psychomotor slowing, and carries higher mortality than hyperactive delirium due to frequent diagnostic delay.
Major neurocognitive disorder subtypes exhibit distinct clinical prototypes: Alzheimer's (early episodic memory loss), Vascular (stepwise executive decline), Lewy Body (hallucinations, parkinsonism, cognitive fluctuations), Frontotemporal (early disinhibition/personality changes), and NPH (wet, wobbly, wacky).
Depression-induced cognitive impairment ('pseudodementia') is characterized by prominent somatic complaints, verbalized distress over memory loss, and 'I don't know' responses on testing, resolving with effective antidepressant treatment.
Last updated: August 2026
Dementia vs. Delirium vs. Depression: Differential Diagnostics & Management
Cognitive and neuropsychiatric complaints in older adults represent one of the most common and challenging clinical presentations in advanced practice primary care. The "3 Ds"— Delirium , Dementia (Major Neurocognitive Disorder), and Depression —frequently co-occur in the same patient, creating diagnostic confusion and risking therapeutic misadventure. For the AGPCNP, executing a rigorous, structured differential diagnosis is paramount to identifying reversible medical emergencies, establishing precise neurocognitive prognoses, and initiating goal-concordant therapies.
1. Master Differential Diagnostic Matrix: The 3 Ds +---------------------------------------------------------------------------------------------------+
- | MASTER DIFFERENTIAL: DELIRIUM vs. DEMENTIA vs. DEPRESSION |
- | |
- | CLINICAL FEATURE DELIRIUM DEMENTIA DEPRESSION |
- | ================ ======== ======== ========== |
- | Onset Acute (hours to days) Insidious (months/years) Subacute (weeks) |
- | Course Fluctuating (wax/wane) Progressive, steady decline Diurnal (AM worse)|
- | Duration Days to weeks Years to decades Months to years |
- | Consciousness Altered / Fluctuating Intact until end stage Intact / Normal |
- | Attention Severely Impaired Intact early, declines late Variable / Intact |
- | Orientation Impaired (fluctuating) Impaired progressively Intact / May miss |
- | Memory Impaired recall/immediate Loss of recent/short-term Patchy / Effortful|
- | Testing Response Incoherent / Inattentive Tries hard, covers errors "I don't know" |
- | Perception Visual Hallucinations common Absent early (except LBD) Rare/Mood-congruent|
- | Reversibility HIGHLY REVERSIBLE Generally IRREVERSIBLE HIGHLY REVERSIBLE |
- +---------------------------------------------------------------------------------------------------+
- Clinical Interrogation of Cognitive Testing Responses
Dementia: Patients typically demonstrate a lack of insight ( anosognosia ), minimize their cognitive deficits, attempt to answer questions cheerfully or make plausible guesses ( confabulation ), and look to family members for reassurance or answers ( head-turning sign ).
Depression ("Pseudodementia"): Patients actively emphasize and lament their memory failures ( "My brain is completely gone, I can't remember anything" ), exhibit profound psychomotor slowing, and respond to cognitive test items with rapid, unmotivated "I don't know" answers without attempting recall.
Delirium: Patients are unable to sustain focused attention long enough to complete testing, display fragmented thinking, exhibit perceptual distortions (illusions/hallucinations), and fluctuate in alertness between somnolence and agitation.
2. Delirium: Pathophysiology, Subtypes & Structured Workup
Delirium is a medical emergency representing acute, diffuse cerebral metabolic failure. The underlying neurobiology involves widespread central cholinergic hypofunction , excess dopaminergic and glutamatergic signaling, and microglial activation triggered by systemic neuroinflammation. +---------------------------------------------------------------------------------------------------+
- | CONFUSION ASSESSMENT METHOD (CAM) ALGORITHM |
- | |
- | FEATURE 1: Acute Onset and Fluctuating Course |
- | - Evidence of acute mental status change from baseline corroborated by family/nursing? |
- | - Does abnormal behavior fluctuate during the day (waxing and waning)? |
- | AND |
- | FEATURE 2: Inattention |
- | - Difficulty focusing attention? (e.g., unable to spell 'WORLD' backward, count down 20 to 1, |
- | or perform digit span test)? Easily distracted by environmental stimuli? |
- | AND |
- | (MUST EXHIBIT EITHER FEATURE 3 OR FEATURE 4) |
- | / \ |
- | / \ |
- | v v |
- | FEATURE 3: Disorganized Thinking FEATURE 4: Altered Level of Consciousness |
- | - Incoherent, rambling, illogical, - Any state other than 'Alert': |
- | tangential flow of ideas, or * Hyperalert / Agitated |
- | unpredictable topic switching. * Lethargic / Somnolent |
- | * Stuporous / Semi-comatose |
- | |
- | DIAGNOSTIC RULE: [Feature 1] + [Feature 2] + EITHER [Feature 3] OR [Feature 4] = DELIRIUM |
- +---------------------------------------------------------------------------------------------------+
- Delirium Motoric Subtypes
Hyperactive Delirium (~20–25%): Agitation, restlessness, emotional lability, hypervigilance, combative behavior, pulling at intravenous lines or urinary catheters, vivid hallucinations. Easiest to recognize.
Hypoactive Delirium (~50–60%): Lethargy, somnolence, psychomotor retardation, apathy, staring into space, decreased verbal output. Most frequently misdiagnosed as depression or worsening dementia and carries the highest mortality rate due to delayed medical evaluation.
Mixed Delirium (~20–25%): Rapid nocturnal-diurnal cycling between hyperactive agitation and daytime hypoactive somnolence.
Etiological Workup: The "I WATCH DEATH" Framework
Letter Etiological Category High-Yield Clinical Triggers & Diagnostic Tests
I Infection Urinary tract infection / urosepsis, aspiration pneumonia, bacteremia, COVID-19, C. diff colitis, meningitis. (Urinalysis/culture, CXR, CBC, Blood cultures) .
W Withdrawal Alcohol withdrawal (Delirium Tremens), benzodiazepine withdrawal, opioid withdrawal. (Urine drug screen, serum alcohol, medication reconciliation) .
A Acute Metabolic Hyponatremia, hypercalcemia, hypoglycemia, severe uremia, acute liver failure/hyperammonemia, acidosis. (CMP, ABG, blood glucose) .
T Trauma Falls, hip fracture, subdural hematoma, rib fractures, recent surgery. (Head CT without contrast, skeletal radiographs) .
C CNS Pathology Acute ischemic stroke, intracranial hemorrhage, transient ischemic attack (TIA), non-convulsive status epilepticus. (Brain MRI/CT, EEG) .
H Hypoxia Acute pulmonary embolism, severe COPD exacerbation, acute heart failure, hypoxemic respiratory failure, severe anemia. (SpO2, ABG, hemoglobin, troponin) .
D Deficiencies Thiamine (Wernicke-Korsakoff syndrome), vitamin B12 deficiency, profound malnutrition. (Serum B12, methylmalonic acid, thiamine level) .
E Endocrine Thyroid storm, severe myxedema coma, acute adrenal insufficiency, DKA / HHS. (TSH, free T4, serum cortisol) .
A Acute Vascular Acute coronary syndrome (silent MI in older adults), hypertensive encephalopathy, aortic dissection. (12-lead ECG, serial cardiac enzymes) .
T Toxins / Drugs Anticholinergics, sedatives, opioids, polypharmacy, poly-substance intoxication. (Beers Criteria review, toxicology) .
H Heavy Metals / Hospital Lead, mercury, sensory deprivation, ICU environment, severe physical restraints, sleep disruption, fecal impaction, acute urinary retention. (Post-void bladder scan, rectal vault exam) .
Delirium Management Principles
Non-Pharmacological Protocols (Hospital Elder Life Program - HELP): First-line and most effective intervention. Includes regular reorientation (clocks, calendars, familiar objects), maintaining circadian sleep-wake cycles (natural daylight, quiet at night), sensory optimization (ensuring working glasses and hearing aids are worn), early physical mobilization, avoidance of physical restraints, and maintaining adequate hydration/nutrition.
Pharmacological Restraint Rules: Antipsychotics have no prophylactic role in delirium and do not shorten delirium duration. Pharmacotherapy (e.g., low-dose Haloperidol 0.5–1 mg or Quetiapine 12.5–25 mg) is strictly indicated only when severe hyperactive agitation threatens immediate physical harm to self or staff (e.g., pulling endotracheal tube). Avoid benzodiazepines entirely (which worsen delirium), unless managing alcohol or sedative withdrawal.
3. Major Neurocognitive Disorders (Dementia Subtypes)
Major Neurocognitive Disorder (DSM-5) requires significant cognitive decline in one or more cognitive domains (complex attention, executive function, learning and memory, language, perceptual-motor, or social cognition) that interferes with independence in everyday activities (requiring assistance with IADLs/ADLs). +---------------------------------------------------------------------------------------------------+
- | NEUROPATHOLOGICAL LOCALIZATION OF DEMENTIAS |
- | |
- | [ALZHEIMER'S DISEASE] |
- | - Medial Temporal Lobes & Hippocampus -> Anterograde Episodic Memory Loss, Anomia, Apraxia |
- | - Neuropathology: Extracellular Beta-Amyloid Plaque deposition & Intracellular Tau Tangles |
- | |
- | [VASCULAR DEMENTIA] |
- | - Subcortical White Matter & Frontostriatal Circuits -> Stepwise Decline, Executive Dysfunction |
- | - Neuropathology: Multiple lacunar infarcts, microvascular ischemic leukoaraiosis |
- | |
- | [LEWY BODY DEMENTIA] |
- | - Cortical & Substantia Nigra Alpha-Synuclein Inclusions -> Visual Hallucinations, Parkinsonism |
- | - Neuropathology: Cytoplasmic Lewy Bodies; Severe Neuroleptic Hypersensitivity |
- | |
- | [FRONTOTEMPORAL DEMENTIA] |
- | - Frontal & Anterior Temporal Lobes -> Early Disinhibition, Loss of Empathy, Hyperorality |
- | - Neuropathology: Pick bodies (tau or TDP-43 inclusions); Preserved Visuospatial Function |
- +---------------------------------------------------------------------------------------------------+
- Detailed Subtype Comparison
Dementia Subtype Primary Epidemiological & Clinical Features Hallmark Neurological Signs Diagnostic Neuroimaging / Biomarkers Specific Pharmacological Considerations
Alzheimer's Disease (AD) 60–70% of all cases. Insidious onset; early progressive loss of short-term episodic memory; spatial disorientation; progressive language impairment. Motor exam completely normal in early/moderate stages; primitive reflexes appear late. Brain MRI: Bilateral hippocampal and medial temporal lobe atrophy.; CSF: Decreased A β 42 \text{A}\beta_{42} A β 42 , elevated phosphorylated tau (p-tau). Cholinesterase inhibitors (Donepezil, Rivastigmine, Galantamine) for mild-to-moderate; Memantine for moderate-to-severe; Anti-amyloid mAbs (Lecanemab) for early AD/MCI with confirmed amyloid.
Vascular Dementia (VaD) 15–20% of cases. Stepwise or fluctuating cognitive decline correlated with cerebrovascular ischemic events; prominent early executive dysfunction (planning, organizing). Focal neurological deficits (hyperreflexia, unilateral weakness, extensor plantar response); gait impairment early. Brain MRI: Extensive subcortical white matter hyperintensities (leukoaraiosis), multiple cortical/lacunar infarcts. Strict cardiovascular risk factor modification (BP control, statins, antiplatelets); Cholinesterase inhibitors have modest benefit.
Lewy Body Dementia (DLB) Core Triad:; 1. Fluctuating cognition with pronounced variations in attention/alertness.; 2. Recurrent, detailed visual hallucinations (people/animals).; 3. Spontaneous parkinsonism (rigidity, bradykinesia). REM sleep behavior disorder (dream enactment); severe autonomic dysfunction (orthostatic syncope); extreme sensitivity to antipsychotics. DaTscan (SPECT): Reduced dopamine transporter uptake in basal ganglia.; Brain MRI: Generalized atrophy without disproportionate hippocampal loss. Cholinesterase inhibitors highly effective for cognition/hallucinations; STRICTLY AVOID first-generation antipsychotics (causes catastrophic rigidity/death); use low-dose Quetiapine or Pimavanserin if essential.
Frontotemporal Dementia (FTD / Pick's) Typical onset earlier (ages 45–65).; • Behavioral variant (bvFTD): Marked personality change, disinhibition, hyperorality, apathy, loss of empathy.; • Language variant (PPA): Progressive loss of word meaning or speech production. Visuospatial skills and orientation remarkably preserved early; hyperreflexia, frontal release signs (grasp, snout reflexes). Brain MRI: Striking, asymmetric frontal and anterior temporal lobar atrophy. Cholinesterase inhibitors and Memantine are INEFFECTIVE and may worsen agitation! Manage behavioral symptoms with SSRIs (Sertraline, Trazodone).
Normal Pressure Hydrocephalus (NPH) Classic Triad: "Wet, Wobbly, and Wacky" ; 1. Gait Disturbance (magnetic gait, apraxia - appears FIRST).; 2. Urinary Incontinence (urge/overflow).; 3. Cognitive Impairment (subcortical executive slowing). Magnetic, wide-based, short-stepped gait (feet appear glued to the floor); preserved strength. Brain MRI: Ventriculomegaly out of proportion to cerebral sulcal atrophy (Evans Index > 0.3 >0.3 > 0.3 ).; High-volume lumbar puncture (30–50 mL tap test) yields dramatic gait improvement. Definitive treatment: Surgical Ventriculoperitoneal (VP) Shunt placement.
4. Dementia Pharmacotherapy & Practice Guidelines +---------------------------------------------------------------------------------------------------+
- | DEMENTIA PHARMACOTHERAPY SPECTRUM |
- | |
- | [CHOLINESTERASE INHIBITORS (ChEIs)] |
- | - Agents: Donepezil (5-10 mg daily), Rivastigmine (oral / transdermal patch), Galantamine |
- | - Mechanism: Reversible inhibition of acetylcholinesterase, increasing synaptic acetylcholine |
- | - Indications: Mild to Moderate Alzheimer's, Lewy Body Dementia, Vascular Dementia |
- | - Adverse Effects: Nausea, diarrhea, anorexia, weight loss, severe bradycardia, syncope, insomnia|
- | - Clinical Pearl: Rivastigmine transdermal patch bypasses GI tract, reducing nausea/diarrhea |
- | |
- | [NMDA RECEPTOR ANTAGONISTS] |
- | - Agent: Memantine (5-20 mg daily, titrate weekly) |
- | - Mechanism: Uncompetitive NMDA receptor antagonist; blocks pathological glutamate excitotoxicity|
- | - Indications: Moderate to Severe Alzheimer's Disease (MMSE <15-20); add to Donepezil |
- | - Adverse Effects: Dizziness, headache, confusion, constipation; dose-reduce in CKD |
- | |
- | [ANTI-AMYLOID MONOCLONAL ANTIBODIES (2023-2026 Landscape)] |
- | - Agents: Lecanemab, Donanemab |
- | - Mechanism: Binds and clears soluble amyloid-beta protofibrils and plaques in cerebral cortex |
- | - Indications: Mild Cognitive Impairment (MCI) or Mild Dementia due to confirmed AD pathology |
- | - Critical Safety Surveillance: Regular Brain MRI monitoring for ARIA (Amyloid-Related Imaging |
- | Abnormalities: ARIA-E [vasogenic edema] and ARIA-H [microhemorrhages/superficial siderosis]); |
- | ApoE ε4 homozygous status carries the highest risk of severe ARIA. |
- +---------------------------------------------------------------------------------------------------+
- Management of Behavioral and Psychological Symptoms of Dementia (BPSD)
Agitation, aggression, wandering, and delusions occur in up to 90% of dementia patients over the disease course.
Non-Pharmacological First (DICE Framework): D escribe the specific behavior; I nvestigate underlying triggers (unmanaged pain, constipation, urinary retention, cold/hot, noisy environment, fear); C reate targeted non-pharmacological caregiver interventions; E valuate efficacy.
FDA Black-Box Warning on Antipsychotics: All first- and second-generation antipsychotics carry an explicit Black-Box Warning for a 1.6- to 1.7-fold increase in all-cause mortality (primarily from stroke, aspiration pneumonia, and sudden cardiac death) when used in older adults with dementia-related psychosis. If non-pharmacologic measures fail and severe psychotic agitation threatens safety, obtain documented surrogate informed consent, use lowest effective dose of atypical antipsychotics (Quetiapine 12.5–25 mg, Risperidone 0.25–0.5 mg), and reassess for tapering within 3–6 months.
5. Geriatric Depression & "Pseudodementia"
Late-life depression often presents atypically with somatic complaints, anorexia, uncharacteristic anxiety, and cognitive complaints rather than classic depressed mood.
Clinical Evaluation and Diagnostic Tools
Geriatric Depression Scale (GDS-15): Validated 15-item binary (Yes/No) questionnaire that excludes somatic symptoms to avoid confounding by physical illness. Score ≥ 5 \ge 5 ≥ 5 suggests depression; score ≥ 10 \ge 10 ≥ 10 is highly sensitive and specific for major depressive episode.
Depression-Induced Cognitive Impairment (Pseudodementia): A reversible syndrome where severe depressive disorder causes pronounced executive dysfunction, psychomotor slowing, and memory retrieval deficits. When treated with effective antidepressant therapy, cognitive performance returns to baseline.
Safe Antidepressant Selection in Older Adults
Preferred First-Line SSRIs: Sertraline (25–100 mg/day) and Escitalopram (5–10 mg/day) have minimal drug-drug interactions and benign cardiovascular profiles. Monitor for SSRI-induced hyponatremia / SIADH and GI bleeding risk.
Agents to Avoid: Fluoxetine (excessively long half-life and potent CYP2D6/CYP3A4 inhibition) and Paroxetine (potent anticholinergic properties causing sedation, constipation, and cognitive worsening).
Alternative Agents: Duloxetine (SNRI; highly effective for co-existing diabetic peripheral neuropathy, fibromyalgia, or chronic osteoarthritis pain; monitor blood pressure); Mirtazapine (Noradrenergic and specific serotonergic antidepressant; potent 5-HT2/3 and H1 blockade promoting appetite stimulation, weight gain, and sedation at low doses 7.5–15 mg, ideal for depressed patients with severe insomnia and cachexia).
6. Board-Yield Summary & Clinical Pearls +---------------------------------------------------------------------------------------------------+
- | ANCC AGPCNP CLINICAL EXAM PEARLS |
- | |
- | - Acute cognitive decline + fluctuating inattention is DELIRIUM until proven otherwise. |
- | Never attribute sudden confusion to 'worsening dementia' without ruling out infection or ADEs.|
- | |
- | - If a clinical vignette describes a patient with fluctuating cognition, spontaneous |
- | parkinsonism, and vivid, detailed visual hallucinations of animals or small children, the |
- | diagnosis is LEWY BODY DEMENTIA. Never prescribe Haloperidol (severe fatal rigidity risk!). |
- | |
- | - A patient presenting with progressive wide-based 'magnetic' gait ataxia, urinary urge |
- | incontinence, and cognitive slowing ('Wet, Wobbly, Wacky') has Normal Pressure Hydrocephalus. |
- | A high-volume therapeutic lumbar puncture is both diagnostic and temporarily curative. |
- | |
- | - In geriatric depression with anorexia and severe insomnia, Mirtazapine 7.5-15 mg at bedtime is |
- | the board-favored agent due to appetite-stimulating and sedating antihistaminic properties. |
- +---------------------------------------------------------------------------------------------------+